Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
About Cellectis
Cellectis (NASDAQ: CLLS) is a clinical-stage biopharmaceutical company at the forefront of gene-editing technologies, dedicated to developing innovative cancer immunotherapies and other therapeutic solutions. Leveraging over 18 years of expertise in genome engineering, Cellectis has established itself as a pioneer in the field, utilizing its proprietary TALEN® (Transcription Activator-Like Effector Nucleases) technology and PulseAgile electroporation system to create precise, next-generation therapies. These tools enable the company to harness the immune system's power to target and eliminate cancer cells effectively.
Core Focus: Allogeneic CAR-T and Gene-Edited HSPCs
Cellectis specializes in developing allogeneic Chimeric Antigen Receptor T-cells (UCART) for immuno-oncology applications. Unlike traditional autologous CAR-T therapies, which require harvesting and engineering a patient’s own cells, Cellectis’s allogeneic approach uses gene-edited donor cells. This innovation offers scalability, reduced manufacturing costs, and faster availability, making it a game-changer in cancer treatment. Additionally, the company is advancing gene-edited hematopoietic stem and progenitor cells (HSPCs) for therapeutic indications beyond oncology, showcasing its versatility in genome editing.
Proprietary Technologies
Cellectis’s competitive edge lies in its proprietary technologies:
- TALEN® Technology: A precise and versatile gene-editing tool that enables targeted modifications to DNA, ensuring high specificity and minimal off-target effects.
- PulseAgile Electroporation System: A cutting-edge delivery platform that enhances the efficiency of introducing genetic material into cells.
These technologies form the backbone of Cellectis’s product pipeline, enabling the development of innovative therapies that address unmet medical needs.
Market Position and Industry Context
Cellectis operates within the rapidly growing fields of immuno-oncology and precision medicine. The global demand for effective cancer therapies continues to rise, driven by advancements in biotechnology and an increasing understanding of the immune system's role in combating diseases. As a clinical-stage company, Cellectis focuses on research and development, with a pipeline of promising product candidates undergoing rigorous clinical trials. However, this stage also presents challenges, including regulatory approvals, high R&D costs, and competition from other biotech firms specializing in gene editing and CAR-T therapies.
Competitive Landscape
Key competitors in the gene-editing and CAR-T therapy space include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics. Cellectis differentiates itself through its allogeneic approach, which offers significant advantages in scalability and cost-effectiveness. By addressing the limitations of autologous therapies, such as manufacturing complexity and patient-specific variability, Cellectis positions itself as a leader in next-generation cancer immunotherapies.
Challenges and Opportunities
While Cellectis’s innovative approach holds immense promise, the company faces several challenges. These include navigating a complex regulatory environment, managing high development costs, and competing in a crowded market. However, the potential rewards are substantial, with successful therapies offering transformative benefits for patients and significant market opportunities. The company’s focus on leveraging proprietary technologies and addressing unmet medical needs positions it well for long-term success.
Conclusion
Cellectis is a trailblazer in the biopharmaceutical industry, combining cutting-edge gene-editing technologies with a commitment to innovation in cancer immunotherapy and beyond. By leveraging its proprietary TALEN® technology and allogeneic approach, the company aims to revolutionize the treatment landscape, offering scalable, cost-effective solutions to some of the most pressing medical challenges. As a clinical-stage entity, Cellectis represents a high-risk, high-reward opportunity within the dynamic biotechnology sector.
Cellectis S.A. (NASDAQ: CLLS) has successfully completed sales of approximately $47 million in American Depositary Shares (ADS) under its ATM program initiated on March 29, 2021. A total of 2,415,630 new ADSs were issued at an average price of $19.50 each. The settlement for the new ordinary shares is expected on April 12, 2021, allowing trading on Euronext Growth and Nasdaq. This follows a shelf registration statement filed with the SEC in June 2020, which is effective for potential investors.
Cellectis S.A. (NASDAQ: CLLS) announced the filing of a prospectus supplement with the SEC related to an At-The-Market (ATM) program, allowing sales of American Depositary Shares (ADS) up to $125 million. The program aims to fund research, development, and manufacturing in the biotechnology space. Notably, this could lead to a dilution of approximately 29.74% based on existing share capital. Jefferies LLC will act as the sales agent, and the program is effective until June 2, 2023.
Cellectis, a clinical-stage biopharmaceutical company, focuses on CAR-T immunotherapies for oncology, utilizing its proprietary TALEN® gene editing technology. The company reported a total of 43,033,680 shares and 49,098,269 voting rights as of February 28, 2021. Cellectis aims to provide innovative UCART product candidates for cancers such as acute myeloid leukemia and multiple myeloma. Headquartered in Paris, Cellectis is listed on both the Nasdaq (CLLS) and Euronext Growth (ALCLS).
Cellectis reported ongoing enrollment in three Phase 1 dose-escalation trials for r/r B-ALL, r/r AML, and r/r MM, with preliminary results of the BALLI-01 study presented at ASH 2020. The company has partnered with Cytovia Therapeutics to develop TALEN® gene-edited NK cell programs and completed construction of manufacturing facilities in Paris and North Carolina. As of December 31, 2020, Cellectis had a cash position of $274 million, extending its cash runway into late 2022. A conference call is scheduled for March 5, 2021, to discuss year-end results and business updates.
Cellectis (Nasdaq: CLLS) will report its financial results for Q4 and full year 2020 on March 4, 2021, post US market close. A conference call will follow on March 5, at 8:00 AM EST. The company is developing innovative allogeneic CAR-T immunotherapies utilizing its proprietary TALEN® gene editing technology. Cellectis focuses on treating unmet needs in multiple cancers, including AML and B-ALL. The announcement comes amid ongoing advancements in its UCART product candidates and a commitment to delivering actionable therapies.
Cytovia Therapeutics and Cellectis have formed a strategic collaboration to develop TALEN® gene-edited iPSC NK and CAR-NK cells. This partnership could yield up to $760 million in milestones for Cellectis. Cellectis will get single-digit royalties on sales of partnered products. Cytovia is responsible for the clinical development of these therapies, aiming for trials by 2022. The collaboration is anticipated to enhance NK cell therapies' efficacy for various cancers, capitalizing on Cellectis' gene-editing expertise to improve safety and effectiveness.
Cellectis, a clinical-stage biopharmaceutical company, is pioneering allogeneic CAR-T immunotherapies using its TALEN® gene editing technology. As of January 31, 2021, the company has a total of 43,029,305 shares and 49,093,894 voting rights. Cellectis focuses on developing UCART product candidates to treat unmet medical needs in various cancers including acute myeloid leukemia and multiple myeloma. The company operates in Paris, New York, and Raleigh, and is listed on both Nasdaq (CLLS) and Euronext Growth (ALCLS).
Cellectis announced a registered direct offering through its subsidiary Calyxt, securing $15 million by selling 3,750,000 shares at $4.00 each. Cellectis will purchase 1,250,000 shares, raising its ownership stake in Calyxt to 64.7%. The offering, set to close around October 20, 2020, will fund general corporate purposes, including advancing product development and TALEN® technology. H.C. Wainwright & Co. acts as the exclusive placement agent. The shares are offered under an effective SEC registration statement.
Cellectis announced updates on its share capital and voting rights as of September 30, 2020. The total number of shares in the capital reached 42,486,133, while the total voting rights amounted to 47,940,528. Specializing in CAR-T immunotherapies, Cellectis focuses on innovative gene editing technologies to treat various cancers, including acute myeloid leukemia and multiple myeloma. The company’s mission is to provide effective UCART product candidates to address unmet medical needs in oncology.
Cellectis announced its commitment to advancing CAR-T immunotherapies, focusing on off-the-shelf gene-edited T-cells for cancer treatment. As of August 31, 2020, the company has 42,486,133 shares outstanding and 47,940,778 voting rights. Their innovative approach leverages TALEN® technology to target a range of cancers including AML, B-ALL, and MM. Headquartered in Paris, Cellectis is publicly traded on both Nasdaq (CLLS) and Euronext Growth (ALCLS). The company aims to meet urgent medical needs in oncology, leveraging over 20 years of gene editing expertise.
FAQ
What is the current stock price of Cellectis (CLLS)?
What is the market cap of Cellectis (CLLS)?
What does Cellectis specialize in?
How does Cellectis differentiate from competitors?
What are Cellectis’s proprietary technologies?
What challenges does Cellectis face?
What is the significance of allogeneic CAR-T therapies?
What market does Cellectis target?
Who are Cellectis’s main competitors?
What stage of development is Cellectis in?
